Biocon Chair Backs Lifestyle-First Approach to Obesity as Generic GLP-1 Uptake Stalls Despite Lower Prices

Kiran Mazumdar-Shaw advocates diet and exercise before GLP-1 drugs — a stance carrying conflict-of-interest weight given Biocon's biosimilar pipeline — while Zerodha's Nithin Kamath notes affordability alone isn't driving adoption of cheaper generics.

ndtv-profit-business · 6/28/2026, 3:32:37 PM · Ask about this →